AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7750917 — intervention group
Group type: EXPERIMENTAL
Intervention: GH 8 IU/m2 3 times/week
Number of subjects: 54
Study 7750917 — intervention group
Group type: EXPERIMENTAL
Intervention: GH 4 IU/m2 6 times/week
Number of subjects: 54
Study 7750917 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinyloestradiol 100 ng/kg body weight/day (for patients older than 12 years)
Number of subjects: 54
Study 7750917 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated adult Dutch patients with Turner syndrome)
Number of subjects: 54
Study 2256009 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine chewing gum
Number of subjects: 496
Study 2256009 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver acetate chewing gum
Number of subjects: 496
Study 2256009 — intervention group
Group type: EXPERIMENTAL
Intervention: Ordinary chewing gum
Number of subjects: 496
Study 2256009 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups combined
Number of subjects: 496
Study 540429 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha‐receptor blockade (phentolamine 10 mg intravenously)
Number of subjects: 27
Study 540429 — intervention group
Group type: EXPERIMENTAL
Intervention: combined alpha‐ and beta‐ receptor blockade (labetalol 100 mg intravenously)
Number of subjects: 27
Study 31641967 — intervention group
Group type: EXPERIMENTAL
Intervention: PBMT + nonsurgical periodontal treatment (NSPT)
Number of subjects: 22
Study 31641967 — intervention group
Group type: COMPARATOR
Intervention: nonsurgical periodontal treatment (NSPT)
Number of subjects: 22
Study 31538180 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine 40 mg
Number of subjects: 56
Study 31538180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 28538312 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric Training (PT) for 8 weeks
Number of subjects: 20
Study 28538312 — intervention group
Group type: COMPARATOR
Intervention: Control group (CTRL)
Number of subjects: 20
Study 25628380 — intervention group
Group type: EXPERIMENTAL
Intervention: Articulated ankle‐foot orthosis
Number of subjects: 18
Study 25628380 — intervention group
Group type: COMPARATOR
Intervention: Rigid carbon fiber footplate attached to a foot orthosis
Number of subjects: 18
Study 23692383 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg diclofenac HPβCD
Number of subjects: 306
Study 23692383 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg diclofenac HPβCD
Number of subjects: 306
Study 23692383 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg diclofenac HPβCD
Number of subjects: 306
Study 23692383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306
Study 21976257 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor seven for acute hemorrhagic stroke (FAST)
Number of subjects: 821
Study 21976257 — intervention group
Group type: EXPERIMENTAL
Intervention: Careful reduction of systolic blood pressure (SBP) by 1–10% in the first 24 h
Number of subjects: 821
Study 21976257 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurological worsening within the first 72 h
Number of subjects: 821
Study 19237898 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of piperacillin (6 patients)
Number of subjects: 13
Study 19237898 — intervention group
Group type: COMPARATOR
Intervention: Bolus dosing of piperacillin (7 patients)
Number of subjects: 13
Study 19237898 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of piperacillin
Number of subjects: 13
Study 19237898 — intervention group
Group type: COMPARATOR
Intervention: Bolus dosing of piperacillin
Number of subjects: 13
Study 17541052 — intervention group
Group type: EXPERIMENTAL
Intervention: Transference-focused psychotherapy
Number of subjects: 90
Study 17541052 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical behavior therapy
Number of subjects: 90
Study 17541052 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic supportive treatment
Number of subjects: 90
Study 15289715 — intervention group
Group type: EXPERIMENTAL
Intervention: Active HVPC electrotherapy
Number of subjects: 0
Study 15289715 — intervention group
Group type: COMPARATOR
Intervention: Sham HVPC (control)
Number of subjects: 0
Study 11769819 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 188
Study 11769819 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 188
Study 9241693 — intervention group
Group type: EXPERIMENTAL
Intervention: Humidified hyperbaric oxygen
Number of subjects: 13
Study 9241693 — intervention group
Group type: COMPARATOR
Intervention: Dry hyperbaric oxygen
Number of subjects: 13
Study 8504970 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminosalicylic acid (5-ASA) enemas
Number of subjects: 63
Study 8504970 — intervention group
Group type: COMPARATOR
Intervention: bismuth citrate-carbomer enemas
Number of subjects: 63
Study 3691321 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrose 8.1 kcal per kg per day
Number of subjects: 8
Study 3691321 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrose 30.7 kcal per kg per day
Number of subjects: 8
Study 29961816 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab plus glucocorticoids
Number of subjects: 0
Study 29961816 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab monotherapy
Number of subjects: 0
Study 29961816 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab treatment
Number of subjects: 0
Study 29961816 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 26645392 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg
Number of subjects: 1556
Study 24195864 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg FeSO4
Number of subjects: 40
Study 24195864 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 22170382 — intervention group
Group type: EXPERIMENTAL
Intervention: Community mobilization (CM) and mobile voluntary counseling and testing (MVCT) with edutainment during evening hours
Number of subjects: 0
Study 22170382 — intervention group
Group type: EXPERIMENTAL
Intervention: Community mobilization (CM) with edutainment
Number of subjects: 0
Study 20420761 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralose (4 mM in 0.9% saline)
Number of subjects: 10
Study 20420761 — intervention group
Group type: COMPARATOR
Intervention: Control (0.9% saline)
Number of subjects: 10
Study 16942867 — intervention group
Group type: EXPERIMENTAL
Intervention: Expiratory muscle training
Number of subjects: 16
Study 16942867 — intervention group
Group type: COMPARATOR
Intervention: Sham training
Number of subjects: 16
Study 16259175 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity ultrasound therapy (20 minutes daily for six weeks)
Number of subjects: 16
Study 16259175 — intervention group
Group type: COMPARATOR
Intervention: Placebo (inactive ultrasound device)
Number of subjects: 16
Study 12070676 — intervention group
Group type: EXPERIMENTAL
Intervention: Balneotherapy (20-min bathing, once a day, five times per week for 3 weeks, total of 15 sessions)
Number of subjects: 42
Study 12070676 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=20)
Number of subjects: 42
Study 10818663 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief psychotherapy
Number of subjects: 0
Study 10818663 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 7674504 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factor modification (very low‐fat vegetarian diet, mild to moderate exercise, stress management, group support)
Number of subjects: 35
Study 7674504 — intervention group
Group type: COMPARATOR
Intervention: Usual care (antianginal therapy)
Number of subjects: 35
Study 7674504 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factor modification
Number of subjects: 35
Study 7674504 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 35
Study 2206076 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral terbutaline, 2.5 to 5 mg every 3 to 4 hours
Number of subjects: 50
Study 2206076 — intervention group
Group type: COMPARATOR
Intervention: Oral magnesium oxide, 200 mg every 3 to 4 hours
Number of subjects: 50
Study 6930206 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (400 mg/day first month, average 585 mg/day second month)
Number of subjects: 13
Study 6930206 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (160 mg/day first month, average 234 mg/day second month)
Number of subjects: 13
Study 6930206 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (higher dose)
Number of subjects: 13
Study 6930206 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol with diuretic
Number of subjects: 13
Study 6930206 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (long term therapy)
Number of subjects: 13
Study 31365109 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment aimed at decreasing systolic BP by 10%-25% within the first 24 hours, achieving systolic BP <140 mm Hg and diastolic BP <90 mm Hg within 7 days, and maintaining this level during hospitalization.
Number of subjects: 4071
Study 31365109 — intervention group
Group type: EXPERIMENTAL
Intervention: Early antihypertensive treatment
Number of subjects: 4071
Study 31365109 — intervention group
Group type: COMPARATOR
Intervention: Control group (discontinued all antihypertensive medications)
Number of subjects: 4071
Study 28647458 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous tibial nerve stimulation (PTNS)
Number of subjects: 205
Study 28647458 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 205
Study 25774975 — intervention group
Group type: EXPERIMENTAL
Intervention: Abductor hop
Number of subjects: 12
Study 25774975 — intervention group
Group type: EXPERIMENTAL
Intervention: Jumping jacks (JJ)
Number of subjects: 12
Study 25774975 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontal kick
Number of subjects: 12
Study 25774975 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-country skiing (CCS)
Number of subjects: 12
Study 25774975 — intervention group
Group type: EXPERIMENTAL
Intervention: Stationary running
Number of subjects: 12
Study 23766737 — intervention group
Group type: EXPERIMENTAL
Intervention: PlayWisely program
Number of subjects: 18
Study 23766737 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 18
Study 19734256 — intervention group
Group type: EXPERIMENTAL
Intervention: Iyengar Yoga (IY) for 12 weeks
Number of subjects: 57
Study 19734256 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC) for 12 weeks
Number of subjects: 57
Study 19303675 — intervention group
Group type: EXPERIMENTAL
Intervention: Low cost behavioral prevention program in preschool settings
Number of subjects: 2658
Study 19303675 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 2658
Study 17143194 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren monotherapy (75, 150 or 300 mg)
Number of subjects: 2776
Study 17143194 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of aliskiren (300 mg) and HCTZ (25 mg)
Number of subjects: 2776
Study 17143194 — intervention group
Group type: COMPARATOR
Intervention: HCTZ monotherapy (6.25, 12.5 or 25 mg)
Number of subjects: 2776
Study 17143194 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2776
Study 15606470 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolate anterior surface IOL (Tecnis Z9000, Pharmacia)
Number of subjects: 12
Study 15606470 — intervention group
Group type: COMPARATOR
Intervention: Biconvex spherical surface IOL (CeeOn 911 A, Pharmacia)
Number of subjects: 12
Study 11841195 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunisolide 500 microg administered twice daily by nebulizer for 4 weeks
Number of subjects: 133
Study 11841195 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 500 microg administered twice daily by nebulizer for 4 weeks
Number of subjects: 133
Study 9743401 — intervention group
Group type: EXPERIMENTAL
Intervention: Paralysis with vecuronium
Number of subjects: 7
Study 9743401 — intervention group
Group type: COMPARATOR
Intervention: No muscle relaxants (unparalyzed)
Number of subjects: 7
Study 8001599 — intervention group
Group type: EXPERIMENTAL
Intervention: New acenocoumarol tablet formulation (12 mg single oral dose)
Number of subjects: 8
Study 8001599 — intervention group
Group type: COMPARATOR
Intervention: New acenocoumarol tablet formulation
Number of subjects: 8
Study 3892994 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose heparin (Heparin Leo 5000 I.U. subcutaneously twice daily)
Number of subjects: 112
Study 3892994 — intervention group
Group type: COMPARATOR
Intervention: Graded compression stockings (TED stockings, Kendall Co.)
Number of subjects: 112
Study 30897995 — intervention group
Group type: EXPERIMENTAL
Intervention: apo(a) production rate (PR)
Number of subjects: 63
Study 30897995 — intervention group
Group type: EXPERIMENTAL
Intervention: apo(a) fractional catabolic rate (FCR)
Number of subjects: 63
Study 30897995 — intervention group
Group type: EXPERIMENTAL
Intervention: apo(a) PR
Number of subjects: 63
Study 30897995 — intervention group
Group type: EXPERIMENTAL
Intervention: apo(a) FCR
Number of subjects: 63
Study 30897995 — intervention group
Group type: EXPERIMENTAL
Intervention: apo(a) PR and FCR
Number of subjects: 63
Study 30897995 — intervention group
Group type: EXPERIMENTAL
Intervention: apo(a) PR and isoform size
Number of subjects: 63
Study 29678962 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter from GP outlining importance of asthma medication (delivered in late July)
Number of subjects: 12179
Study 29678962 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 12179
Study 29678962 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter from GP
Number of subjects: 12179
Study 26656775 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 54
Study 26656775 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic exercise
Number of subjects: 54
Study 26656775 — intervention group
Group type: COMPARATOR
Intervention: Nonexercise control
Number of subjects: 54
Study 24281825 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIT)
Number of subjects: 16
Study 24281825 — intervention group
Group type: COMPARATOR
Intervention: Continuous Moderate-Intensity Training (CMT)
Number of subjects: 16
Study 22317607 — intervention group
Group type: EXPERIMENTAL
Intervention: Labor Gym (LG) program
Number of subjects: 35
Study 20553538 — intervention group
Group type: EXPERIMENTAL
Intervention: Health professional facilitated sessions (three one-hour group education and goal setting sessions over 7 weeks)
Number of subjects: 121
Study 20553538 — intervention group
Group type: COMPARATOR
Intervention: Control group (one-hour health promotion talk)
Number of subjects: 121
Study 18029171 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole (1mg, n=29)
Number of subjects: 90
Study 18029171 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (2.5mg, n=29)
Number of subjects: 90
Study 18029171 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane (25mg, n=32)
Number of subjects: 90
Study 17174448 — intervention group
Group type: EXPERIMENTAL
Intervention: UVC disinfection
Number of subjects: 183
Study 17174448 — intervention group
Group type: COMPARATOR
Intervention: Antiseptic wiping
Number of subjects: 183
Study 17174448 — intervention group
Group type: COMPARATOR
Intervention: Dry wiping
Number of subjects: 183
Study 15300210 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 46
Study 15300210 — intervention group
Group type: COMPARATOR
Intervention: IV opioids
Number of subjects: 46
Study 12170987 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana
Number of subjects: 0
Study 12170987 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral THC
Number of subjects: 0
Study 12170987 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 0
Study 8922763 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms.kg‐1
Number of subjects: 70
Study 8922763 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 0.25 mg.kg‐1
Number of subjects: 70
Study 8922763 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 70
Study 1348403 — intervention group
Group type: EXPERIMENTAL
Intervention: xamoterol
Number of subjects: 15
Study 1348403 — intervention group
Group type: COMPARATOR
Intervention: digoxin
Number of subjects: 15
Study 3994353 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular ceruletide
Number of subjects: 24
Study 3994353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 30343977 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedical follow-up
Number of subjects: 224
Study 30343977 — intervention group
Group type: COMPARATOR
Intervention: Onsite follow-up
Number of subjects: 224
Study 27738970 — intervention group
Group type: EXPERIMENTAL
Intervention: RYGB
Number of subjects: 14
Study 27738970 — intervention group
Group type: EXPERIMENTAL
Intervention: SG
Number of subjects: 14
Study 27738970 — intervention group
Group type: EXPERIMENTAL
Intervention: Both RYGB and SG
Number of subjects: 14
Study 27738970 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent diabetes post-operatively
Number of subjects: 14
Study 27435894 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine (4 to 512 μg)
Number of subjects: 11
Study 27435894 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 11
Study 27435894 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine
Number of subjects: 11
Study 27435894 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid body ablation
Number of subjects: 11
Study 24296500 — intervention group
Group type: EXPERIMENTAL
Intervention: New Nordic Diet (NND)
Number of subjects: 62
Study 24296500 — intervention group
Group type: COMPARATOR
Intervention: Average Danish Diet (ADD)
Number of subjects: 62
Study 24296500 — intervention group
Group type: EXPERIMENTAL
Intervention: High-P/B group
Number of subjects: 62
Study 24296500 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-P/B group
Number of subjects: 62
Study 22972843 — intervention group
Group type: EXPERIMENTAL
Intervention: Emtricitabine/tenofovir disoproxil fumarate (PrEP)
Number of subjects: 0
Study 19067728 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegvisomant (20 mg daily for 14 days)
Number of subjects: 3
Study 17457091 — intervention group
Group type: EXPERIMENTAL
Intervention: NNRTI-based regimen
Number of subjects: 0
Study 17457091 — intervention group
Group type: COMPARATOR
Intervention: PI-based regimen
Number of subjects: 0
Study 14969833 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine 100 mg/d administered preoperatively in HBV active replication group (15 recipients)
Number of subjects: 25
Study 14969833 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine 100 mg/d administered preoperatively in HBV inactive replication group (7 recipients)
Number of subjects: 25
Study 14969833 — intervention group
Group type: COMPARATOR
Intervention: Control group (3 recipients)
Number of subjects: 25
Study 11401118 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary angioplasty (n = 1,327)
Number of subjects: 9906
Study 11401118 — intervention group
Group type: COMPARATOR
Intervention: Thrombolysis (n = 8,579)
Number of subjects: 9906
Study 9072566 — intervention group
Group type: COMPARATOR
Intervention: Extracorporeal shock wave lithotripsy (ESWL) monotherapy
Number of subjects: 50
Study 9072566 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined percutaneous nephrostolithotomy with ESWL
Number of subjects: 50
Study 8201485 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (0.1 mg/kg intravenously at 6 to 12 postnatal hours and every 24 hours for two more doses)
Number of subjects: 61
Study 8201485 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 61
Study 8201485 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 61
Study 3310942 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg four times a day (short-term phase)
Number of subjects: 104
Study 3310942 — intervention group
Group type: COMPARATOR
Intervention: Placebo (short-term phase)
Number of subjects: 104
Study 3310942 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg at bedtime (maintenance phase)
Number of subjects: 104
Study 3310942 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maintenance phase)
Number of subjects: 104
Study 29288590 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampcare Effective Swallowing Protocol (ESP), treatment 5 days/week for 4 weeks.
Number of subjects: 30
Study 29288590 — intervention group
Group type: COMPARATOR
Intervention: Usual care (speech and language therapy dysphagia care).
Number of subjects: 30
Study 27404223 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid®
Number of subjects: 16
Study 27404223 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 24454698 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic interval training
Number of subjects: 49
Study 24454698 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal volitional interval training
Number of subjects: 49
Study 24454698 — intervention group
Group type: COMPARATOR
Intervention: Walking (active control)
Number of subjects: 49
Study 22623396 — intervention group
Group type: EXPERIMENTAL
Intervention: D2 at 5 μg/d
Number of subjects: 40
Study 22623396 — intervention group
Group type: EXPERIMENTAL
Intervention: D2 at 10 μg/d
Number of subjects: 40
Study 22623396 — intervention group
Group type: EXPERIMENTAL
Intervention: D3 at 5 μg/d
Number of subjects: 40
Study 22623396 — intervention group
Group type: EXPERIMENTAL
Intervention: D3 at 10 μg/d
Number of subjects: 40
Study 22623396 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 19395648 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine extended release (GXR)
Number of subjects: 0
Study 19395648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18042229 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A 100 units
Number of subjects: 86
Study 18042229 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 15925520 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused attention on a gap between collinear elements
Number of subjects: 0